Extranodal nasal NK/T cell lymphoma prognostic marker, application thereof, prognostic prediction model and construction method thereof

Abstract

The invention discloses an extranodal nasal NK/T cell lymphoma prognostic marker, an application thereof, a prognostic prediction model and a construction method thereof. The prognostic marker is remarkably related to disease staging and Ki67 positive rate, and the prognostic marker is CD20; it is found for the first time that the infiltration density of CD20 positive cells in the extranodal nasalNK/T cell lymphoma tumor tissue is positively correlated with the survival time of a patient, and is negatively correlated with the disease staging of the patient; it shows that CD20 can be used as aprediction index for good prognosis of the patient; the prognostic marker CD20 can make up for the deficiency of good prognostic prediction indexes in the ENKTCL field; the construction method of theprognosis prediction model is simple; the density of CD20 positive cells in a tumor tissue slice of the patient is detected by combining an immunohistochemical method with a slice microscanning technology and the like, so that a patient prognosis prediction model is constructed; and the patient prognosis prediction model has great significance in guiding individualized treatment of clinical extranodal nasal NK/T cell lymphoma.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a prognostic marker for extranodal nasal type NK / T cell lymphoma and its application, a prognostic prediction model and its construction method. Background technique [0002] Lymphoma is a malignant tumor originating from the lymphatic hematopoietic system. According to the tumor cells, it is divided into two types: non-Hodgkin's lymphoma (non-Hodgkin's lymphoma) and Hodgkin's lymphoma (Hodgkin's lymphoma). Extra Nodal NK / T cell lymphoma (ENKTCL) belongs to extranodal non-Hodgkin's lymphoma, which is a subtype of lymphoma with unique biological characteristics. It accounts for 5% to 10% of non-Hodgkin's lymphoma; it often occurs in young and middle-aged people, the median age of onset is about 40 years old, and the male to female incidence ratio is about (2~4): 1; the disease distribution has obvious geographical and ethnic differences It has a high incidence rate in Asia and South Amer...

AI Technical Summary

Problems solved by technology

[0005] However, previous studies have only found markers of myeloid immune cells (CD14 + Peripheral blood mononuclear cells and CD68 + tumor-associated macrophages) as prognostic markers, and both markers suggest poor patient prognosis

But in fact, ENKTCL t

Images